David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma. A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few options to treat Ewing's sarcoma, a rare orphan pediatric disease, Salarius is testing a new treatment that can provide hope to patients by inhibiting the LSD1 enzyme and effectively addressing the dysregulation.
@salariuspharma
#ewingsarcoma #ewingssarcoma #rarediseases
Salariuspharma.com
Download the transcript here
Empowered Patient Podcast